MedPath

Takeda Pharmaceutical Company Ltd

🇯🇵Japan
Ownership
-
Established
1925-01-01
Employees
-
Market Cap
$47.5B
Website
http://www.takeda.co.jp/

Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency

Recruiting
Conditions
Multiple Myeloma
Secondary Immunodeficiency (SID)
Interventions
Other: No Intervention
First Posted Date
2023-05-30
Last Posted Date
2025-03-25
Lead Sponsor
Takeda
Target Recruit Count
75
Registration Number
NCT05879757
Locations
🇦🇷

Instituto Privado de Investigaciones Clinicas de Cordoba, Cordoba, Argentina

🇨🇿

Fakultni nemocnice Plzen, Pilsen, Czechia

🇨🇿

Vseobecna fakultni Nemocnice, Prague, Czechia

and more 24 locations

A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING)

Withdrawn
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Other: No Intervention
First Posted Date
2023-05-18
Last Posted Date
2023-10-18
Lead Sponsor
Takeda
Registration Number
NCT05863819
Locations
🇨🇳

Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, P. R. China, Shanghai, China

A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease

Phase 3
Recruiting
Conditions
Crohn's Disease
Interventions
First Posted Date
2023-05-01
Last Posted Date
2024-10-16
Lead Sponsor
Takeda
Target Recruit Count
408
Registration Number
NCT05837897
Locations
🇨🇳

Guangzhou First People's Hospital, Guangzhou, Guangdong, China

🇨🇳

The Second Hospital of Anhui Medical University, Hefei, Anhui, China

🇨🇳

Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, China

and more 37 locations

A Study of TAK-227 in Healthy Adults

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2023-04-19
Last Posted Date
2024-08-06
Lead Sponsor
Takeda
Target Recruit Count
24
Registration Number
NCT05818956
Locations
🇺🇸

Celerion, Inc., Tempe, Arizona, United States

A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

Phase 2
Recruiting
Conditions
Narcolepsy Type 1
Interventions
First Posted Date
2023-04-18
Last Posted Date
2024-08-15
Lead Sponsor
Takeda
Target Recruit Count
500
Registration Number
NCT05816382
Locations
🇩🇪

Somni Bene Institut fur Medizinische Forschung und Schlafmedizin Schwerin GmbH, Schwerin, Mecklenburg-Vorpommern, Germany

🇮🇹

Fondazione PTV Policlinico Tor Vergata, Roma, Lazio, Italy

🇳🇴

University of Oslo, Oslo, Norway

and more 49 locations

A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery

Phase 2
Terminated
Conditions
Sleep Apnea
Interventions
Drug: Placebo
First Posted Date
2023-04-14
Last Posted Date
2025-02-10
Lead Sponsor
Takeda
Target Recruit Count
41
Registration Number
NCT05814016
Locations
🇺🇸

Helen Keller Hospital, Sheffield, Alabama, United States

🇺🇸

Mayo Clinic - PPDS - Hospital, Phoenix, Arizona, United States

🇺🇸

UCSD, La Jolla, California, United States

and more 16 locations

A Study to Describe Mothers' and Babies' Outcomes After Exposure to HyQvia During Pregnancy

Completed
Conditions
Exposure During Pregnancy
Interventions
First Posted Date
2023-04-07
Last Posted Date
2023-09-25
Lead Sponsor
Takeda
Target Recruit Count
7
Registration Number
NCT05803200
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome

Conditions
Hunter Syndrome
First Posted Date
2023-04-03
Last Posted Date
2025-04-22
Lead Sponsor
Takeda
Registration Number
NCT05795361
Locations
🇺🇸

Phoenix Childrens Hospital, Phoenix, Arizona, United States

🇺🇸

The Nemours Foundation, Wilmington, Delaware, United States

🇺🇸

Jackson Memorial Hospital University of Miami, Miami, Florida, United States

and more 19 locations

Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Conditions
Thrombotic Thrombocytopenic Purpura (TTP)
First Posted Date
2023-03-15
Last Posted Date
2025-02-24
Lead Sponsor
Takeda
Registration Number
NCT05770219

A Study to Learn About Metachromatic Leukodystrophy (MLD) in Children in Spain

Withdrawn
Conditions
Metachromatic Leukodystrophy (MLD)
Interventions
Other: No Intervention
First Posted Date
2023-03-06
Last Posted Date
2024-01-12
Lead Sponsor
Takeda
Registration Number
NCT05755568
Locations
🇪🇸

Hospital Clinico Universitario de Santiago, Santiago de Compostela, A Coruna, Spain

🇪🇸

Hospital Universitario y Politecnico La Fe, Valencia, Spain

🇪🇸

Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain

and more 7 locations
© Copyright 2025. All Rights Reserved by MedPath